A group of 100 totally or subtotally myeloperoxidase (MPO)-deficient individuals was compared to a reference population of 118 probands selected at random. Data for a protective effect of the deficiency against cardiovascular damage are presented. On the other hand, a significantly higher occurrence of severe infections and chronic inflammatory processes was noted among the deficient patients. An increased incidence of cancer among the MPO-deficient individuals was not demonstrated.

Keywords:
Cancer, Cardiovascular atheroma, Infection, Inflammation, Myeloperoxidase deficiency, Myocardial infarction
1.
Jolivalt C, Leininger-Muller B, Drozdz R, Nakasalski JW, Siest G: Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Neurosci Lett 1996;210:61–64.
2.
Lehrer RI, Cline MJ: Leukocyte myeloperoxidase deficiency and disseminated candidiasis. J Clin Invest 1969;48:1478–1488.
3.
Proceedings of the Symposium Recent Developments in Myeloperoxidase Deficiency, Luxembourg, Oct 1996. J Mol Med 1998:76:659–698.
4.
2nd International Conference on the Peroxidase Family. Fraueninsel-Lake Chiemsee, Sept/Oct 1998.
5.
Lanza F, Musto P, Franzè D: Hereditary myeloperoxidase deficiency syndrome. Ital J Med 1985;1:45–52.
6.
Lanza F, Fietta A, Spisani S, Castoldi GL, Traniello S: Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? J Clin Lab Immunol 1987;22:175–180.
7.
Lanza F, Giuliani A L, Amelotti F, Spisani S, Traniello S, Castoldi GL: Depressed neutrophil-mediated tumor cell cytotoxicity in subjects affected by hereditary myeloperoxidase deficiency and secondary neoplasia. Haematologia 1988;72:355–358.
8.
Kutter D, Al Haidari K, Thoma J: Myeloperoxidase deficiency: Simple methods for its diagnosis and significance of different forms. Klin Lab 1994;40:342–346.
9.
Heinecke JW: Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory diseases. J Lab Clin Med 1999;133:321–325.
10.
Larrocha C, Fernandez de Castro M, Fontan G, Viloria A, Fernandez-Chacon JL, Jimenez C: Hereditary myeloperoxidase deficiency: Study of 12 cases. Scand J Haematol 1982;29:389–397.
11.
Davis AT, Brunning RD, Quie PC: Polymorphonuclear leukocyte myeloperoxidase deficiency in a patient with myelomonocytic leukemia. N Engl J Med 1971;285:789–790.
12.
Cech P, Papathanassiou A, Boreux G, Roth P, Miescher PA: Hereditary myeloperoxidase deficiency. Blood 1979;53:403–411.
13.
Bos AJ, Weening RS, Hamers MN, Wever R, Behrendt H, Roos D: Characterization of hereditary partial myeloperoxidase deficiency. J Lab Clin Med 1979;99:589–600.
14.
Ross WD: Totale Myeloperoxidasedeficienz. Blutbild Atlas. Munich, Bayer Diagnostics, 1993.
15.
Huhn D, Belhohradsky BH, Haas R: Familiärer Myeloperoxidasedefekt und akute myeloische Leukämie. Acta Haematol1978;59:129–143.
16.
Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, Richar WJ: Myeloperoxidase deficiency. Ann Intern Med 1981;95:293–301.
17.
Nauseef WM, Root RK, Malech HL: Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency. J Clin Invest 1983;71:1297–1307.
18.
Dri P, Cramer R, Soranzo MR, Comin A, Miotti V, Patriarca P: New approaches to the detection of myeloperoxidase deficiency. Blood 1982;60:323–327.
19.
Moosmann K, Bojanovsky A: Rezidivierende Candidosis bei Myeloperoxidasemangel. Monatsschr Kinderheilk 1975;123:408–409.
20.
Undritz E: Die Alius-Grignaschi-Anomalie: Der erblich-konstitutionelle Peroxydasedefekt der Neutrophilen und der Monozyten. Blut 1966;14:129–136.
21.
Grignaschi VJ, Sperperato AM, Eetcheverry MJ, Macario AJL: Un nuevo quadro citoquimi- co: Negatividad espontanea de las recciones de peroxidasas, oxidasas y lipido en la progenia neutrofila y en los monocitos de dos hermanos. Rev Assoc Med Argent 1963;77:218.
22.
Tobler A, Selsted ME, Miller CW, Johnson KR, Novotny MJ, Rovera G, Koeffler HP: Evidence for a pretranslational defect in hereditary and acquired myeloperoxidase deficiency. Blood 1989;73:1986–1989.
23.
Gerber CE, Kuçi S, Zipfel M, Niethammer D, Bruchelt G: Phagocytic activity and oxidative burst of granulocytes in persons with myeloperoxidase deficiency. Eur J Clin Chem Clin Biochem 1996;34:901–908.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.